R1 RCM Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

R1 RCM wird ein jährliches Gewinn- und Umsatzwachstum von 55.4% bzw. 11.2% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 55.7% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 3.5% betragen.

Wichtige Informationen

57.7%

Wachstumsrate der Gewinne

59.0%

EPS-Wachstumsrate

Healthcare Gewinnwachstum	19.3%
Wachstumsrate der Einnahmen	11.4%
Zukünftige Eigenkapitalrendite	4.4%
Analystenabdeckung	Good
Zuletzt aktualisiert	04 Sep 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

R1 RCM Inc. (NASDAQ:RCM) Shares Could Be 40% Below Their Intrinsic Value Estimate

Jun 05

R1 RCM Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

May 06

R1 RCM (NASDAQ:RCM) Might Have The Makings Of A Multi-Bagger

Mar 17

Is R1 RCM Inc. (NASDAQ:RCM) Trading At A 42% Discount?

Jan 06

R1 RCM slides 7% on secondary stock offering by selling shareholder

Sep 08

R1 RCM's (NASDAQ:RCM) Promising Earnings May Rest On Soft Foundations

Aug 11

R1 RCM GAAP EPS of -$0.07 misses by $0.11, revenue of $391.9M in-line

Aug 03

R1 RCM: Long-Term Growth Story Intact Following Cloudmed Acquisition

Jul 19

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:RCM - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	3,215	140	397	577	10
12/31/2025	2,930	57	261	410	15
12/31/2024	2,540	-95	125	228	10
6/30/2024	2,380	-40	203	312	N/A
3/31/2024	2,313	-33	229	332	N/A
12/31/2023	2,254	3	238	340	N/A
9/30/2023	2,212	-35	151	251	N/A
6/30/2023	2,135	-65	68	168	N/A
3/31/2023	1,966	-91	-93	13	N/A
12/31/2022	1,806	-63	-103	-10	N/A
9/30/2022	1,672	-1	-95	-2	N/A
6/30/2022	1,556	45	-13	63	N/A
3/31/2022	1,518	91	189	242	N/A
12/31/2021	1,475	-505	205	257	N/A
9/30/2021	1,404	-495	190	230	N/A
6/30/2021	1,332	-512	108	145	N/A
3/31/2021	1,293	-526	62	107	N/A
12/31/2020	1,270	47	11	60	N/A
9/30/2020	1,256	14	61	121	N/A
6/30/2020	1,250	16	55	115	N/A
3/31/2020	1,231	3	-16	43	N/A
12/31/2019	1,186	-9	53	114	N/A
9/30/2019	1,135	-22	11	68	N/A
6/30/2019	1,084	-42	33	83	N/A
3/31/2019	997	-41	54	99	N/A
12/31/2018	869	-64	-15	18	N/A
9/30/2018	746	-99	-4	19	N/A
6/30/2018	619	-88	-3	23	N/A
3/31/2018	510	-92	N/A	39	N/A
12/31/2017	450	-76	N/A	21	N/A
9/30/2017	416	-28	N/A	-22	N/A
6/30/2017	418	-3	N/A	-57	N/A
3/31/2017	327	-36	N/A	-116	N/A
12/31/2016	593	65	N/A	-87	N/A
9/30/2016	555	68	N/A	-100	N/A
6/30/2016	445	17	N/A	-57	N/A
3/31/2016	458	35	N/A	-8	N/A
12/31/2015	117	-84	N/A	-24	N/A
9/30/2015	96	-107	N/A	-39	N/A
6/30/2015	171	-65	N/A	-23	N/A
3/31/2015	208	-55	N/A	-71	N/A
12/31/2014	210	-80	N/A	-77	N/A
9/30/2014	247	-56	N/A	-22	N/A
6/30/2014	174	-103	N/A	-47	N/A
3/31/2014	490	102	N/A	28	N/A
12/31/2013	505	130	N/A	54	N/A
9/30/2013	-220	0	N/A	52	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: RCM wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (2.4%).

Ertrag vs. Markt: RCM wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: RCM wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: RCMDie Einnahmen des Unternehmens (11.2% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.4% pro Jahr).

Hohe Wachstumseinnahmen: RCMDie Einnahmen des Unternehmens (11.2% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: RCMDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (3.5%).

R1 RCM Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates upgraded to US$0.21 loss

Consensus EPS estimates fall by 47%

Price target decreased by 10% to US$15.03

R1 RCM Inc. Revises Earnings Guidance for the Year 2024

Consensus EPS estimates upgraded to US$0.0021 loss

R1 RCM Inc. Provides Earnings Guidance for the Fiscal Year 2024

Recent updates

Consensus EPS estimates upgraded to US$0.21 loss

Consensus EPS estimates fall by 47%

Second quarter 2024 earnings: EPS exceeds analyst expectations

Price target decreased by 10% to US$15.03

TowerBrook Capital Partners L.P. and Clayton, Dubilier & Rice, LLC agreed to acquire remaining 64% stake in R1 RCM Inc. (NasdaqGS:RCM) from TowerBrook Capital Partners L.P. and others for $6.3 billion.

R1 RCM Inc. to Report Q2, 2024 Results on Aug 07, 2024

R1 RCM Inc. Revises Earnings Guidance for the Year 2024

First quarter 2024 earnings: EPS and revenues miss analyst expectations

R1 RCM Inc., Annual General Meeting, May 22, 2024

R1 RCM Inc. to Report Q1, 2024 Results on May 08, 2024

Consensus EPS estimates upgraded to US$0.0021 loss

Voss Capital - R1 RCM Inc.: Bull Case Achievable Despite Negative Sentiment

New minor risk - Earnings quality

R1 RCM Inc. Provides Earnings Guidance for the Fiscal Year 2024

New Mountain Partners V (AIV-D), L.P. and New Mountain Investments V, L.L.C., managed by New Mountain Capital, L.L.C. submits a non-binding proposal to acquire remaining 67.56906% stake in R1 RCM Inc. (NasdaqGS:RCM) from TowerBrook Investors, Ltd and others for approximately $4 billion.

Full year 2023 earnings: EPS misses analyst expectations

Coliseum Capital Issues an Open Letter to the Board of R1 RCM

R1 RCM Inc. Appoints Pamela L. Spikner as Principal Accounting Officer

R1 RCM Inc. (NasdaqGS:RCM) completed the acquisition of Acclara Solutions, LLC from Providence St. Joseph Health for $680 million.

R1 RCM Inc. to Report Q4, 2023 Results on Feb 27, 2024

R1 RCM Inc. Appoints Clay Ashdown as Director

R1 RCM Inc. (NasdaqGS:RCM) entered into the Purchase Agreement to acquire Acclara Solutions, LLC from Providence St. Joseph Health.

R1 RCM Inc. (NasdaqGS:RCM) entered into the Purchase Agreement to acquire Acclara Solutions, LLC from Providence St. Joseph Health.

R1 RCM Receives Notice Of Filing Delinquency from Nasdaq

R1 RCM Receives Notice Of Filing Delinquency from Nasdaq

R1 RCM Inc. announced delayed 10-Q filing

Price target decreased by 8.8% to US$19.53

R1 RCM Inc. Provides Revenue Guidance for the Year 2023

Third quarter 2023 earnings released: EPS: US$0.003 (vs US$0.071 loss in 3Q 2022)

Now 26% undervalued after recent price drop

R1 RCM Inc. Announces Janie Wade Resigns from its Board of Directors

Now 20% undervalued after recent price drop

R1 RCM Inc. to Report Q3, 2023 Results on Nov 02, 2023

Calculating The Fair Value Of R1 RCM Inc. (NASDAQ:RCM)

Returns At R1 RCM (NASDAQ:RCM) Are On The Way Up

Lead Independent Director notifies of intention to sell stock

Price target increased by 7.8% to US$21.70

R1 RCM Inc. Provides Earnings Guidance for the Year of 2023

Second quarter 2023 earnings released: EPS: US$0.001 (vs US$0.069 loss in 2Q 2022)

Is Now An Opportune Moment To Examine R1 RCM Inc. (NASDAQ:RCM)?

R1 RCM Inc. to Report Q2, 2023 Results on Aug 02, 2023

Why We're Not Concerned About R1 RCM Inc.'s (NASDAQ:RCM) Share Price

Senior VP recently sold US$487k worth of stock

R1 RCM Inc. (NASDAQ:RCM) Shares Could Be 40% Below Their Intrinsic Value Estimate

President recently sold US$327k worth of stock

President notifies of intention to sell stock

R1 RCM Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

R1 RCM Inc. Provides Earnings Guidance for the Year 2023

First quarter 2023 earnings: EPS exceeds analyst expectations

R1 RCM (NASDAQ:RCM) Might Have The Makings Of A Multi-Bagger

CEO & Director recently bought US$1.0m worth of stock

Full year 2022 earnings: EPS misses analyst expectations

R1 RCM Inc. Provides Earnings Guidance for the Fiscal Year 2023

Price target increased by 7.3% to US$16.18

R1 RCM Inc. to Report Q4, 2022 Results on Feb 16, 2023

Consensus forecasts updated

R1 RCM Inc. Announces Chief Financial Officer Changes

Is R1 RCM Inc. (NASDAQ:RCM) Trading At A 42% Discount?

R1 RCM Inc. Appoints Janie Wade as a Director of the Company, Effective January 1, 2023

R1 RCM Inc. Announces Retirement of Albert Zimmerli from the Board of Directors, Effective January 1, 2023

Price target decreased to US$15.55

Price target decreased to US$27.82

R1 RCM Inc. Provides Earnings Guidance for the Year 2022

R1 RCM Inc. to Report Q3, 2022 Results on Nov 08, 2022

R1 RCM slides 7% on secondary stock offering by selling shareholder

Key Executive recently sold US$1.0m worth of stock

R1 RCM Inc. Appoints Brian Dean as Director

R1 RCM's (NASDAQ:RCM) Promising Earnings May Rest On Soft Foundations

Key Executive exercised options and sold US$1.2m worth of stock